M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug BioPharma DiveIf consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix.M&A / DealsHematologyRead full story pharminent March 25, 2026 (Last updated: March 25, 2026) BioPharma Dive If consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix. M&A / DealsHematologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Karyopharm myeloma drug yields mixed data in myelofibrosis trialNext: Sarepta sees early success with RNAi drugs from Arrowhead Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
